1. Home
  2. NXGL vs JAGX Comparison

NXGL vs JAGX Comparison

Compare NXGL & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NexGel Inc

NXGL

NexGel Inc

HOLD

Current Price

$0.53

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.78

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXGL
JAGX
Founded
1997
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.9M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
NXGL
JAGX
Price
$0.53
$0.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.00
$60.00
AVG Volume (30 Days)
144.6K
101.6K
Earning Date
05-11-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
24.00
82.42
EPS
N/A
N/A
Revenue
$11,421,000.00
$11,511,000.00
Revenue This Year
$50.77
$61.58
Revenue Next Year
$46.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
31.46
N/A
52 Week Low
$0.33
$0.22
52 Week High
$2.89
$8.00

Technical Indicators

Market Signals
Indicator
NXGL
JAGX
Relative Strength Index (RSI) 58.14 24.51
Support Level $0.48 $0.60
Resistance Level $0.62 $0.99
Average True Range (ATR) 0.05 0.09
MACD 0.01 0.03
Stochastic Oscillator 84.93 15.07

Price Performance

Historical Comparison
NXGL
JAGX

About NXGL NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: